In Q3 2023, Avoro Capital Advisors held 38 positions worth $6.1B. They initiated 5 new positions and exited 3. Their largest holding was HZNP ($809.8M). Portfolio value shrank -9.3% versus the prior quarter.
Frequently asked questions
What stocks did Avoro Capital Advisors own in Q3 2023?
Avoro Capital Advisors held 38 biotech stocks in their 13F portfolio in Q3 2023. Their top positions include HZNP, UTHR, ARGX, SRPT, APLS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Avoro Capital Advisors's portfolio worth in Q3 2023?
Avoro Capital Advisors's tracked biotech portfolio was worth $6.1B across 38 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Avoro Capital Advisors buy in Q3 2023?
Avoro Capital Advisors initiated 5 new positions in Q3 2023, including GPCR, AKRO, RCKT, CERE, TSHA. They also increased 7 existing positions.
What did Avoro Capital Advisors sell in Q3 2023?
Avoro Capital Advisors fully exited 3 positions in Q3 2023, including AMLX, MRSN, DSGN. They also trimmed 13 existing positions.
Is Avoro Capital Advisors a biotech fund?
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Want AI analysis, insider signals, and catalyst overlays for Avoro Capital Advisors?
View latest Avoro Capital Advisors portfolio →